Genscript Biotech (1548) Stock Statistics & Valuation Metrics

Genscript Biotech has a market cap or net worth of HK$33.28B. The enterprise value is HK$4.80B.

Genscript Biotech has 2,180,594,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genscript Biotech’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 0.19%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Genscript Biotech had revenue of 594.49M and earned 2.96B in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was 79.86M and capital expenditures -134.03M, giving a free cash flow of -54.17M billion.

Genscript Biotech pays an annual dividend of HK$0.012, resulting in a dividend yield of ―

Genscript Biotech upcoming earnings date is ―, ―.

Genscript Biotech as a current ratio of 2.72, with Debt / Equity ratio of 16.75%

In the past 12 months, Genscript Biotech has paid 2.98M in taxes.

Genscript Biotech EV to EBITDA ratio is 47.57, with an EV/FCF ratio of -46.35.

Genscript Biotech has HK$621.18M in cash and marketable securities with $723.74M in debt, giving a net cash position of HK$102.55M billion.

Gross margin is 53.63%, with operating margin of 1.56%, and net profit margin of 498.22%.

The average price target for Genscript Biotech is HK$16.01, which is 11.43% higher than the current price. The consensus rating is Hold